Blog

Jill Feldman: Hope and reality are NOT mutually exclusive

Jill Feldman/henryford.com

Oct 29, 2024, 22:00

Jill Feldman: Hope and reality are NOT mutually exclusive

Jill Feldman, Co-Founder EGFR Resisters, shared a post by Katsuaki Maehara, Director of Medical Education Colleagues, on X, adding:

“I can tell you firsthand the devastation of thinking you are ‘cured,’ only to learn you aren’t. Hope and reality are NOT mutually exclusive. The conversation around stage III NSCLC needs to shift so patients have realistic expectations. With a 35% 5-year survival rate, using the word CURE, is FALSE HOPE.

People with breast cancer or prostate cancer with distant metastasis have the same 5-year survival. Considering the stealth of lung cancer, how many Stage III lung cancers are more advanced stage disease? There is a reason lung cancer has been called the ‘silent killer.'”

Jill Feldman

Quoting Katsuaki Maehara‘s post:

“EGFRm Unresectable Stage III

LAURA and POLESTAR

INDIRECT

Tend to ‘high’ disease progression or death. (IMO)

Are EGFRm positive lung cancers still highly malignant ? (IMO)

It seems as if it is a systemic disease. (IMO)”

Jill Feldman

More posts featuring Jill Feldman and Katsuaki Maehara on oncodaily.com

Jill Feldman is a lung cancer patient and advocate. She is the Co-Founder EGFR Resisters, an advocacy group of EGFR positive lung cancer patients who are resistant to targeted treatment. She is the Past President of the LUNGevity Foundation, Deputy Chair of IASLC’s patient advisory board and a member of The Chicago Institute of Translational Medicine’s patient advisory board. Jill is a member of the programmatic panel for the Department of Defense Lung Cancer Research Program, a planning committee member on IASLC’s North America Conference on Lung cancer and as a member of the the ECOG-ACRIN Research Group’s patient advocate committee and thoracic committee.